Product Alias

MHC, MY-ESO-1, CT6.1, LAGE-2, CTAG1, CTAG1B, ESO1CTAG, LAGE2A, NY-ESO-1

Species

Human

Expression sequence

Gly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M) and SLLMWITQV peptide

Accession

A0A140T913(HLA-A*02:01)&P61769(B2M)&SLLMWITQV

Label

C-His-Avi

Expression system

HEK293

Molecular weight

The protein has a predicted MW of 50.5 kDa. Due to glycosylation, the protein migrates to 51-56 kDa based on SDS-PAGE result.

Purity

> 95% as determined by SDS-PAGE and HPLC.

Endotoxin

< 1.0 EU per μg by the LAL method.

Preparation

Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.

Appearance

Lyophilized Powder

Biological Activity

【ELISA Data】 Immobilized Anti-HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQV) Antibody, hFc Tag at 1μg/ml (100μl/well) on the plate. Dose response curve for Biotinylated Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQV) Monomer, His Tag with the EC50 of 31.3ng/ml determined by ELISA.

Reconstitution method

Centrifuge before opening the lid. Reconstitute the lyophilized protein with distilled water to a concentration of more than 100 μg/mL. It is recommended to aliquot the protein into the amount required for each experiment when using it for the first time to avoid repeated freezing and thawing.